On 17 September 2026, a ClinicalTrials.gov event listing marked the Phase 3 study of finerenone for primary completion. However, the trial record lists its overall status as withdrawn and enrollment as 0 participants; it reports no outcome measurements or analyses.
Background
The study was designed to compare the clinical benefit of finerenone with a fixed-dose combination of extended-release torsemide and spironolactone in patients with hypertension and chronic kidney disease. Hypertension is the condition listed in the trial record. The supplied information does not describe finerenone’s drug class or mechanism, prior approvals, or the prevalence of these conditions.
Trial design
The registry describes this as a Phase 3 study, identified as NCT07223502. Its brief title specifies a comparison in patients with hypertension and chronic kidney disease. Listed interventions include a fixed-dose combination of spironolactone and extended-release torsemide, and stabilized doses of a loop diuretic with finerenone. The record lists planned enrollment as 0 and provides no primary-outcome entries. It does not provide further details on the study design or comparator allocation.
What this means
The primary-completion event label should not be read as evidence that the trial enrolled participants or generated clinical results: the same record reports a withdrawn status and zero enrollment. No efficacy, safety, or comparative-benefit conclusions can be drawn from the information supplied. The listing describes the intended comparison but does not establish whether it was conducted.
Source
Source: ClinicalTrials.gov, study registry record for “A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease,” event dated 17 September 2026. Available at clinicaltrials.gov/study/NCT07223502.